Skip to main content
OpenTrials
Completed

NCT Number: NCT00970814

Levetiracetam XR in Very Heavy Drinkers

The primary objectives of this study are to assess the efficacy of levetiracetam XR in increasing the percentage of subjects with no heavy drinking days and in reducing the weekly percentage of heavy drinking days in subjects with alcohol dependence confirmed by DSM-IV criteria and who frequently consume 10 or more drinks per drinking day for men and 8 or more drinks per drinking day for women (designated as "very heavy" drinkers).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Johns Hopkins School of Medicine, Baltimore, Maryland, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The subject must be at least 18 years of age.
  • The subject must have a DSM-IV diagnosis of current alcohol dependence.
  • The subject must be seeking treatment for alcohol dependence and desires a reduction or cessation of drinking.
  • The subject must be able to verbalize understanding of the consent form, able to provide written informed consent, verbalize willingness to complete study procedures, able to understand written and oral instructions in English and able to complete the questionnaires required by the protocol.
  • If the subject is female and of child bearing potential, she must agree to use at least one of the following methods of birth control, or she must be surgically sterile or postmenopausal:
  • oral contraceptives
  • contraceptive sponge
  • patch
  • barrier (diaphragm or condom)
  • intrauterine contraceptive system
  • levonorgestrel implant
  • medroxyprogesterone acetate contraceptive injection
  • complete abstinence from sexual intercourse, and/or
  • hormonal vaginal contraceptive ring.
  • The subject must be able to take oral medication, willing to adhere to the medication regimen, and willing to return for regular visits.
  • The subject must complete all psychological assessments required at screening and baseline.
  • The subject must provide evidence of stable residence in the last 2 months prior to randomization, have reasonable transportation arrangements to the study site, and have no plans to move within the next 3 months or unresolved legal problems. Subjects must provide contact information of someone, such as a family member, spouse, or significant other, who may be able to contact the subject in case of a missed clinic appointment.
  • The subject must have a breath alcohol concentration (BAC) equal to 0.000 when s/he signed the informed consent document.

Treatment and study plan

BBCET

Behavioral

11 BBCET sessions

Levetiracetam XR

Drug

500mg - 2000mg Once per day 16 weeks

Sugar pill

Drug

500mg - 2000mg Once per day 16 weeks

Primary outcomes

  1. The Percentage of Subjects With no Heavy Drinking Days During Study Weeks 5 Through 14.

    Time frame: Weeks 5-14

    A heavy drinking day is 5+ drinks per day for men and 4+ drinks per day for women based on self report.

  2. The Percentage of Heavy Drinking Days Per Week During Study Weeks 5 Through 14.

    Time frame: Study Weeks 5-14

    A heavy drinking day is 5+ drinks per day for men and 4+ drinks per day for women based on self report.

Secondary outcomes

  1. The Number of Drinks Per Drinking Day Study Weeks 5-14.

    Time frame: Study Weeks 5-14

    based on self report

Sponsors and collaborators

Lead sponsor

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Nih

Registry information

Official study title

A Phase 2, Double Blind, Placebo Controlled Trial to Assess the Efficacy Of Levetiracetam Extended Release in Very Heavy Drinkers

Acronym: NCIG 002

Important dates

Study start
2009
Primary completion
2010
Study completion
2010
First posted
Sep 2, 2009
Registry last updated
Aug 28, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.